These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 31401877)

  • 21. Prediction of preeclampsia with angiogenic biomarkers. Results from the prospective Odense Child Cohort.
    Andersen LB; Dechend R; Jørgensen JS; Luef BM; Nielsen J; Barington T; Christesen HT
    Hypertens Pregnancy; 2016 Aug; 35(3):405-19. PubMed ID: 27159383
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Use of Soluble FMS-like Tyrosine Kinase 1/Placental Growth Factor Ratio in the Clinical Management of Pre-eclampsia.
    Govender N; Moodley J; Naicker T
    Afr J Reprod Health; 2018 Dec; 22(4):135-143. PubMed ID: 30632730
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rule-in and rule-out of pre-eclampsia using DELFIA Xpress PlGF 1-2-3 and sFlt-1: PlGF ratio.
    Bremner L; Gill C; Seed PT; Conti-Ramsden F; Webster L; Fleminger J; Chappell LC; Shennan A; Bramham K
    Pregnancy Hypertens; 2022 Mar; 27():96-102. PubMed ID: 34979346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prediction of adverse maternal outcomes of early severe preeclampsia.
    Mirkovic L; Tulic I; Stankovic S; Soldatovic I
    Pregnancy Hypertens; 2020 Oct; 22():144-150. PubMed ID: 32979729
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Changes in circulating concentrations of soluble fms-like tyrosine kinase-1 and placental growth factor measured by automated electrochemiluminescence immunoassays methods are predictors of preeclampsia.
    Leaños-Miranda A; Campos-Galicia I; Isordia-Salas I; Rivera-Leaños R; Romero-Arauz JF; Ayala-Méndez JA; Ulloa-Aguirre A
    J Hypertens; 2012 Nov; 30(11):2173-81. PubMed ID: 22902831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An sFlt-1:PlGF ratio of 655 is not a reliable cut-off value for predicting perinatal outcomes in women with preeclampsia.
    Stolz M; Zeisler H; Heinzl F; Binder J; Farr A
    Pregnancy Hypertens; 2018 Jan; 11():54-60. PubMed ID: 29523274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Application of the concetrations ratio of soluble receptor tyrosine kinase type 1, and placental growth factor for short-term prediction and diagnosis of preeclampsia].
    Bubeníková Š; Cíchová A; Roubalová L; Durdová V; Vlk R
    Ceska Gynekol; 2016; 81(4):272-278. PubMed ID: 27882748
    [TBL] [Abstract][Full Text] [Related]  

  • 28. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes.
    Salahuddin S; Wenger JB; Zhang D; Thadhani R; Karumanchi SA; Rana S
    Hypertens Pregnancy; 2016 Aug; 35(3):330-45. PubMed ID: 27028795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Urinary and Serum Angiogenic Markers in Women With Preexisting Diabetes During Pregnancy and Their Role in Preeclampsia Prediction.
    Zen M; Padmanabhan S; Zhang K; Kirby A; Cheung NW; Lee VW; Alahakoon TI
    Diabetes Care; 2020 Jan; 43(1):67-73. PubMed ID: 31601637
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of N-terminal pro-B natriuretic peptide to soluble fms-like tyrosine kinase-1/placental growth factor ratio > 38 improves prediction of pre-eclampsia requiring delivery within 1 week: a longitudinal cohort study.
    Sabriá E; Lequerica-Fernández P; Lafuente-Ganuza P; Eguia-Ángeles E; Escudero AI; Martínez-Morillo E; Barceló C; Álvarez FV
    Ultrasound Obstet Gynecol; 2018 Jun; 51(6):758-767. PubMed ID: 29498431
    [TBL] [Abstract][Full Text] [Related]  

  • 31. First and Second Trimester Serum sFlt-1/PlGF Ratio and Subsequent Preeclampsia: A Systematic Review.
    Yusuf AM; Kahane A; Ray JG
    J Obstet Gynaecol Can; 2018 May; 40(5):618-626. PubMed ID: 28927814
    [TBL] [Abstract][Full Text] [Related]  

  • 32. N-terminal pro B-type natriuretic peptide and angiogenic biomarkers in the prognosis of adverse outcomes in women with suspected preeclampsia.
    Álvarez-Fernández I; Prieto B; Rodríguez V; Ruano Y; Escudero AI; Álvarez FV
    Clin Chim Acta; 2016 Dec; 463():150-157. PubMed ID: 27983995
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio and Time to Delivery in Women With Suspected Preeclampsia.
    Zeisler H; Llurba E; Chantraine F; Vatish M; Staff AC; Sennström M; Olovsson M; Brennecke SP; Stepan H; Allegranza D; Dinkel C; Schoedl M; Dilba P; Hund M; Verlohren S
    Obstet Gynecol; 2016 Aug; 128(2):261-269. PubMed ID: 27399996
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Placental growth factor and soluble fms-like tyrosine kinase-1 are useful markers for the prediction of preeclampsia but not for small for gestational age neonates: a longitudinal study.
    Rizos D; Eleftheriades M; Karampas G; Rizou M; Haliassos A; Hassiakos D; Vitoratos N
    Eur J Obstet Gynecol Reprod Biol; 2013 Dec; 171(2):225-30. PubMed ID: 24035323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical interpretation and implementation of the sFlt-1/PlGF ratio in the prediction, diagnosis and management of preeclampsia.
    Verlohren S; Brennecke SP; Galindo A; Karumanchi SA; Mirkovic LB; Schlembach D; Stepan H; Vatish M; Zeisler H; Rana S
    Pregnancy Hypertens; 2022 Mar; 27():42-50. PubMed ID: 34915395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiogenic Markers Predict Pregnancy Complications and Prolongation in Preeclampsia: Continuous Versus Cutoff Values.
    Saleh L; Vergouwe Y; van den Meiracker AH; Verdonk K; Russcher H; Bremer HA; Versendaal HJ; Steegers EAP; Danser AHJ; Visser W
    Hypertension; 2017 Nov; 70(5):1025-1033. PubMed ID: 28847893
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers and the Prediction of Adverse Outcomes in Preeclampsia: A Systematic Review and Meta-analysis.
    Lim S; Li W; Kemper J; Nguyen A; Mol BW; Reddy M
    Obstet Gynecol; 2021 Jan; 137(1):72-81. PubMed ID: 33278298
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical implementation of the sFlt-1/PlGF ratio to identify preeclampsia and fetal growth restriction: A prospective cohort study.
    Herraiz I; Simón E; Gómez-Arriaga PI; Quezada MS; García-Burguillo A; López-Jiménez EA; Galindo A
    Pregnancy Hypertens; 2018 Jul; 13():279-285. PubMed ID: 30177066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. An intermediate sFlt-1/PlGF ratio indicates an increased risk for adverse pregnancy outcome.
    Hoffmann J; Ossada V; Weber M; Stepan H
    Pregnancy Hypertens; 2017 Oct; 10():165-170. PubMed ID: 29153672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic evaluation of the sFlt-1/PlGF ratio for the short-term prediction of preeclampsia in a Japanese cohort of the PROGNOSIS Asia study.
    Ohkuchi A; Masuyama H; Yamamoto T; Kikuchi T; Taguchi N; Wolf C; Saito S
    Hypertens Res; 2021 Jul; 44(7):822-829. PubMed ID: 33594274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.